Get the Stockscreener App
8.77
5.50%
-0.51
Personalis Inc stock is traded at $8.77, with a volume of 4.32M.
It is down -5.50% in the last 24 hours and up +9.49% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$9.28
Open:
$9.37
24h Volume:
4.32M
Relative Volume:
3.14
Market Cap:
$778.81M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.8978
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
-8.26%
1M Performance:
+9.49%
6M Performance:
+50.95%
1Y Performance:
+144.97%
1-Day Range:
$8.765
$9.39
1-Week Range:
$8.765
$9.848
52-Week Range:
$2.8262
$11.40
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.77 | 824.10M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
Is Personalis Inc 04X a good long term investmentResistance Breakout Alerts & Free Risk Assessment and Control - earlytimes.in
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds - Yahoo Finance
Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 38% But Its P/S Still Looks Reasonable - 富途牛牛
Personalis (NASDAQ:PSNL) Stock Price Down 4.8%What's Next? - MarketBeat
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - MarketBeat
Personalis Outpaces The Market With Cancer Test Breakthroughs - Finimize
Is Personalis Inc. (04X) stock undervalued by metricsEarnings Miss & Short-Term High Return Strategies - Newser
Geode Capital Management LLC Buys 851,422 Shares of Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. (04X) stock maintain strong growthWeekly Volume Report & Growth Focused Investment Plans - Newser
Will Personalis Inc. (04X) stock beat Nasdaq index returns2025 Short Interest & Real-Time Volume Spike Alerts - Newser
Will Personalis Inc. (04X) stock outperform Dow JonesMarket Risk Summary & Fast Moving Market Watchlists - Newser
How Personalis Inc. stock performs during Fed tightening cycles2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - Newser
Will Personalis Inc. stock reach Wall Street targetsInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Personalis (PSNL) Rating Maintained and Price Target Raised by M - GuruFocus
Personalis (NASDAQ:PSNL) Shares Gap Down After Insider Selling - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Q2 2025 Earnings Call Transcript - MSN
Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL), Dyadic International (DYAI) and NeurAxis, Inc. (NRXS) - The Globe and Mail
Piper Sandler Healthcare Conference - MarketScreener
Personalis Announces $100M Stock Offering Amendment - The Globe and Mail
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells 103,668 Shares of Stock - MarketBeat
Personalis files prospectus supplement for up to $100 million stock offering - Investing.com India
Personalis files prospectus supplement for up to $100 million stock offering By Investing.com - Investing.com South Africa
Personalis, Inc. Announces $100 Million Stock Offering - TradingView
Personalis CFO and COO Aaron Tachibana Sells Over 100K Shares - TradingView
COO Tachibana Sells 103,668 ($1.1M) Of Personalis Inc [PSNL] - TradingView
Insiders Of Personalis Make A Tidy Sum Selling At US$7.14 - simplywall.st
Personalis Stock: A Growth Inflection Is Imminent (NASDAQ:PSNL) - Seeking Alpha
Personalis (NASDAQ:PSNL) Hits New 12-Month HighHere's What Happened - MarketBeat
Personalis Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
COO Tachibana Files To Sell 103,668 Of Personalis Inc [PSNL] - TradingView
Personalis says CMS revises reimbursement rate for Personal test for post-treatment surveillance of cancers - marketscreener.com
Personalis Says CMS Revises Reimbursement Rate For Personal Test For Post-Treatment Surveillance Of Cancers - TradingView
Personalis receives updated Medicare reimbursement rates for cancer monitoring tests - Investing.com India
Personalis, Inc. Announces Revised Medicare Reimbursement Rates - TradingView
[8-K] Personalis, Inc. Reports Material Event | PSNL SEC FilingForm 8-K - Stock Titan
How Analyst Views Are Shifting as Personalis Transforms Its Growth Story - Yahoo Finance
Personalis Inc buy BiotechBee - sharewise.com
BTIG Maintains Personalis (PSNL) Buy Recommendation - MSN
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 68,679 Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. stock recover faster than marketWeekly Profit Report & Fast Moving Market Watchlists - newser.com
Why retail investors favor Personalis Inc. stockJuly 2025 WrapUp & Fast Gain Swing Alerts - newser.com
Can Personalis Inc. stock resist market sell offsLong Setup & Free Technical Confirmation Trade Alerts - newser.com
Will Personalis Inc. (04X) stock benefit from Fed rate cuts2025 Market Sentiment & Daily Market Momentum Tracking - newser.com
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Nov 25 '25 |
Sale |
10.78 |
103,668 |
1,117,541 |
164,458 |
1.15%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):